Activated protein C (APC) resistance, determined with a thrombin‐generation‐based APC
resistance test, may explain risk differences of venous thrombosis in users of second‐and …

Recent studies suggest that low‐dose oral contraceptives may cause acquired resistance to
activated protein C (APC). The aims of this study were to determine whether hormone …

Resistance to activated protein C (APC) is at present considered the most frequent
laboratory abnormality in patients with deep‐vein thrombosis. An increased risk for venous …

Both activated protein C (APC) resistance and protein C deficiency are associated with an
increased risk for venous thrombosis. To assess their tendencies to venous thrombosis, we …

Activated protein C (APC) resistance caused by the factor V Leiden mutation is associated
with an increased risk of venous thrombosis. We investigated whether a reduced response …

Epidemiological studies have shown that women who use third‐generation oral
contraceptives (OC) containing desogestrel, gestodene or norgestimate have a higher risk of …

Several hereditary and acquired risk factors for venous thromboembolism (VTE) are
associated with impaired down-regulation of thrombin formation via the protein C pathway …

Resistance to activated protein C (APC) has been recently identified as a common
abnormality of the clotting system that significantly increases the risk of venous …

Oral contraceptive (OC) use is associated with an increased risk of venous
thromboembolism. Previous data reported higher thrombotic risk in women using third …

Resistance to activated protein C (APC) is often associated with a mutation in factor V (factor
VLeiden). Individuals without factor VLeiden who exhibit a response in functional APC …